<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174250</url>
  </required_header>
  <id_info>
    <org_study_id>6002-015</org_study_id>
    <nct_id>NCT02174250</nct_id>
  </id_info>
  <brief_title>The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.</brief_title>
  <official_title>Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Pharmaceutical Development, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether Rifampin affects blood levels of istradefylline
      in humans. Rifampin could possibly decrease istradefylline levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUC0 ∞) and Observed maximum plasma concentration (Cmax) of istradefylline</measure>
    <time_frame>Intermittently for a total of 62 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events, and non-serious adverse events</measure>
    <time_frame>Continuously for up to 74 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Istradefylline 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Day 1, istradefylline 40mg then crossover to Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin 300mg BID + istradefylline 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2: Days 1-20 rifampin 300mg BID + istradefylline 40mg Day 8 only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istradefylline 40 mg</intervention_name>
    <description>On Day 1, istradefylline 1 × 40-mg tablet administered alone</description>
    <arm_group_label>Istradefylline 40mg</arm_group_label>
    <arm_group_label>Rifampin 300mg BID + istradefylline 40mg</arm_group_label>
    <other_name>KW-6002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin 300mg BID + istradefylline 40mg Day 8 only</intervention_name>
    <description>On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration</description>
    <arm_group_label>Rifampin 300mg BID + istradefylline 40mg</arm_group_label>
    <other_name>rifadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy non-smoking male and post-menopausal female subjects

          -  Body Mass Index: 18.0-35.0 kg/m2, inclusive

          -  Subjects must not be taking drugs that are moderate to potent inhibitors of CYP3A4 or
             CYP1A2.

          -  Subjects without clinically significant medical history in the judgment of the
             investigator

          -  Subjects without clinically significant laboratory or ECG abnormalities

        Exclusion Criteria:

          -  Females that are pregnant or lactating

          -  Administration of an investigational drug within 30 days or 5 elimination half-lives
             of such investigational drug, whichever is longer, prior to study drug administration,
             or planned administration of another investigational product or procedure during the
             subject's participation in this study;

          -  Known history of treatment for drug or alcohol addiction within the previous 12
             months;

          -  Subjects with an average alcohol intake of more than 2 units per day or 14 units per
             week up to 48 hours prior to the istradefylline dose on Day 1. One unit of alcohol is
             ½ pint of beer (285 mL) or 1 glass of spirits (25 mL) or 1 glass of wine (125 mL);

          -  Donated or lost &gt; 500 mL of blood within 3 months prior to istradefylline dose on Day
             1 of Period 1;

          -  Positive test results for human immunodeficiency virus (HIV) or Hepatitis B surface
             antigen, or Hepatitis C;

          -  Positive test results for drugs of abuse at screening;

          -  Unable, or unwilling to tolerate multiple venipunctures;

          -  Difficulty fasting or eating the standard meals that will be provided;

          -  Use of tobacco or nicotine-containing products within 90 days of the study start to
             the Follow-up visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Cantillon, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Kyowa Hakko Kirin Pharma, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Hakko Kirin Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion, Inc.</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Istradefylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

